CytoVeris develops optical probes utilizing multispectral autofluorescence imaging and explainable AI to enhance intraoperative tissue visualization for surgical oncologists. This technology addresses the challenge of incomplete tumor resections, which can lead to higher rates of complications and the need for additional surgeries.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MIFounders
Product
Problem
Incomplete tumor resections during cancer surgery lead to higher complication rates, the need for additional surgeries, and increased risk of recurrence. Surgeons face the challenge of precisely removing cancerous tissue while preserving healthy tissue and critical functions. Current methods lack real-time, accurate visualization of tumor margins, hindering optimal surgical decision-making.
Solution
CytoVeris is developing a specimen imaging technology that utilizes multispectral autofluorescence (AF) imaging and explainable AI to enhance intraoperative tissue visualization for surgical oncologists. The technology identifies target tissue through the detection of intrinsic biomolecular markers, providing real-time insights without the use of imaging agents or dyes. This AI-powered approach aims to increase the precision of cancer resection, reduce the need for secondary operations and additional treatments, and improve patient outcomes. By providing surgeons with easy-to-interpret tools, CytoVeris enables smarter, more efficient, and more effective tissue visualization during surgery.
Target Audience
The primary target audience includes surgical oncologists specializing in breast conservation surgeries, transurethral resection of bladder tumors (TURBT), and radical prostatectomies.
Features
- Multispectral autofluorescence imaging for real-time visualization of tissue characteristics
- Explainable AI algorithms to aid in the identification of cancerous tissue and margin assessment
- Dye-free imaging process, eliminating the need for exogenous contrast agents
- Seamless integration with existing surgical workflows, requiring fewer resources
- Potential for integration into robotic surgical procedures